PE20171095A1 - Acidos grasos novedosos y su uso en la conjugacion con biomoleculas - Google Patents

Acidos grasos novedosos y su uso en la conjugacion con biomoleculas

Info

Publication number
PE20171095A1
PE20171095A1 PE2016002771A PE2016002771A PE20171095A1 PE 20171095 A1 PE20171095 A1 PE 20171095A1 PE 2016002771 A PE2016002771 A PE 2016002771A PE 2016002771 A PE2016002771 A PE 2016002771A PE 20171095 A1 PE20171095 A1 PE 20171095A1
Authority
PE
Peru
Prior art keywords
biomolecules
conjugation
fatty acids
acid
novel fatty
Prior art date
Application number
PE2016002771A
Other languages
English (en)
Inventor
Chikwendu Ibebunjo
Alexandra Marshall Bruce
Avirup Bose
David Weninger Barnes
Ken Yamada
Aaron Kanter
Alokesh Duttaroy
Louise Clare Kirman
Aimee Richardson Usera
Frederic Zecri
Jun Yuan
Changgang Lou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20171095A1 publication Critical patent/PE20171095A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

Se refiere a un conjugado de GDF15 que comprende una biomolecula enlazada a un acido graso por medio de un enlazador, en donde en acido graso tiene las siguientes formulas A1, A2 o A3; donde R1 es CO2H o H; R2, R3 y R4 son H, OH, entre otros; Ak es alquileno de 6 a 30 atomos de carbono ramificado; n, m y p son enteros entre 6 y 30 o amidas, entre otros. Es un acido preferente: acido 2-undecil-manolico, entre otros. Tambien se refiere a una combinacion y una composicion farmaceutica que la comprende. Dicho conjugado es util en el tratamiento de enfermedades metabolicas, diabetes mellitus tipo 2, pancreatitis, entre otros
PE2016002771A 2014-06-23 2015-06-18 Acidos grasos novedosos y su uso en la conjugacion con biomoleculas PE20171095A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US201562107016P 2015-01-23 2015-01-23

Publications (1)

Publication Number Publication Date
PE20171095A1 true PE20171095A1 (es) 2017-08-07

Family

ID=53491695

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002771A PE20171095A1 (es) 2014-06-23 2015-06-18 Acidos grasos novedosos y su uso en la conjugacion con biomoleculas

Country Status (37)

Country Link
US (4) US10588980B2 (es)
EP (2) EP3157571B1 (es)
JP (5) JP6636959B2 (es)
KR (2) KR102559975B1 (es)
CN (3) CN107073130B (es)
AP (1) AP2016009585A0 (es)
AU (1) AU2015280351C1 (es)
CA (1) CA2953480A1 (es)
CL (1) CL2016003281A1 (es)
CR (1) CR20160596A (es)
CU (1) CU24455B1 (es)
CY (1) CY1125006T1 (es)
DK (1) DK3157571T3 (es)
EA (1) EA039074B1 (es)
EC (1) ECSP17004665A (es)
ES (1) ES2905479T3 (es)
GT (1) GT201600263A (es)
HK (1) HK1232160A1 (es)
HR (1) HRP20220152T1 (es)
HU (1) HUE057845T2 (es)
IL (1) IL248990B (es)
JO (1) JO3813B1 (es)
LT (1) LT3157571T (es)
MA (1) MA40278A (es)
MX (1) MX367520B (es)
MY (1) MY193993A (es)
PE (1) PE20171095A1 (es)
PH (1) PH12016502294A1 (es)
PL (1) PL3157571T3 (es)
PT (1) PT3157571T (es)
RS (1) RS62907B1 (es)
SG (2) SG10201912965TA (es)
SI (1) SI3157571T1 (es)
TN (1) TN2016000558A1 (es)
TW (3) TWI701048B (es)
UY (1) UY36186A (es)
WO (1) WO2015200078A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
KR102376451B1 (ko) 2013-07-31 2022-03-23 암젠 인크 성장 분화 인자 15(ｇｄｆ-15) 작제물
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
RU2019126483A (ru) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
EP3610029A1 (en) 2017-04-11 2020-02-19 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
WO2018213082A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
CN111183234A (zh) 2017-10-11 2020-05-19 雷杰纳荣制药公司 在表达pnpla3 i148m变异的患者的肝病治疗中对hsd17b13的抑制
EP3727423B1 (en) * 2017-12-22 2024-05-22 Novartis AG Treatment of metabolic disorders with fgf21 variants
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
CN112543869A (zh) 2018-08-10 2021-03-23 诺华股份有限公司 Gfral细胞外结构域和使用方法
MX2021001590A (es) 2018-08-10 2021-07-02 Univ Massachusetts Oligonucleótidos modificados dirigidos a snp.
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
TW202100563A (zh) * 2019-04-23 2021-01-01 南韓商Ｌｇ化學股份有限公司 融合多肽及其用途與製備方法、核酸分子、重組載體、重組細胞以及用於增強生長/分化因子15或其功能變體的活體內穩定性的方法
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
US11746354B2 (en) 2019-07-19 2023-09-05 Inari Agriculture Technology, Inc. Homology dependent repair genome editing
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
AU2020380587A1 (en) 2019-11-04 2022-01-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
JP2023503722A (ja) * 2019-11-26 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド 核酸および半減期モチーフを含む化合物
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
CN115243727A (zh) * 2020-01-13 2022-10-25 西纳福克斯股份有限公司 经由环加成的双侧官能化抗体
CN115666656A (zh) * 2020-01-13 2023-01-31 西纳福克斯股份有限公司 通过环加成双侧功能化抗体
CN115768483A (zh) * 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
EP4351628A1 (en) * 2021-05-21 2024-04-17 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2022271786A1 (en) 2021-06-23 2022-12-29 University Of Massachusetts Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for reducing or preventing tissue fibrosis
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
WO2024030367A2 (en) * 2022-08-01 2024-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acid-d-amino acid peptides conjugates as anaplerotic compounds for use in treating propionic acidemia, methylmalonic acidurias, and energy metabolic disorders
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
WO1983004412A1 (en) 1982-06-11 1983-12-22 National Research Development Corporation Amphipathic compounds
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE69120645T2 (de) 1990-12-26 1997-02-13 Ricoh Kk Reversible wärmeempfindliche Aufzeichnungszusammensetzung, Aufzeichnungsmedium, Aufzeichnungsverfahren und Anzeigevorrichtung, die das Aufzeichnungsmedium verwendet
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
NZ310370A (en) 1995-06-22 2001-04-27 St A TGF-beta like cytokine designated pCL13
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
NZ334592A (en) 1996-09-11 2000-10-27 Ortho Mcneil Pharm Inc Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
DE69838986T2 (de) 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
AU2001247899A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
AU2001250182B2 (en) 2000-04-20 2006-06-08 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
CA2444098C (en) 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
EP1638963B1 (en) 2003-05-20 2009-09-09 Novartis AG N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
EP1704254A2 (en) 2004-01-14 2006-09-27 Janssen Pharmaceutica N.V. Methods of using peroxisome proliferator-activated receptor alpha target genes
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2005099747A1 (en) 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CA2632095A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
AR058567A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
JP2010536717A (ja) 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
WO2009042798A1 (en) 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Methods for treating fibrosis by modulating cellular senescence
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CA2718148C (en) 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
MX342677B (es) 2008-10-24 2016-10-07 Novartis Ag * Pirrolin-carboxi-lisina biosintéticamente generada y modificaciones de proteínas específicas del sitio por medio de la derivación química de residuos de pirrolin-carboxi-lisina y pirrolisina.
CA2741921A1 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20130053433A1 (en) 2010-01-06 2013-02-28 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
US9394343B2 (en) 2011-07-05 2016-07-19 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US10022256B2 (en) 2012-11-30 2018-07-17 Novartis Ag Methods for making conjugates from disulfide-containing proteins
HUE039848T2 (hu) 2012-12-21 2019-02-28 Hoffmann La Roche Peptidek oxitocin agonistákként
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
AU2014212640B2 (en) 2013-01-30 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN105492026A (zh) 2013-07-03 2016-04-13 奥尔德生物制药公司 使用抗cgrp抗体的葡萄糖代谢的调节
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
CN105612174A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
KR102376451B1 (ko) 2013-07-31 2022-03-23 암젠 인크 성장 분화 인자 15(ｇｄｆ-15) 작제물
EA201691075A1 (ru) 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
CN106102775A (zh) 2014-02-07 2016-11-09 效应物治疗公司 治疗纤维变性疾病的方法
KR101852804B1 (ko) 2014-05-01 2018-04-27 후지필름 가부시키가이샤 적외선 센서, 근적외선 흡수 조성물, 감광성 수지 조성물, 화합물, 근적외선 흡수 필터 및 촬상 장치
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
JP6768527B2 (ja) 2014-06-20 2020-10-14 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170107248A1 (en) 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3237440A1 (en) 2014-12-22 2017-11-01 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3828199A1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
US20200237923A1 (en) 2015-10-14 2020-07-30 The Johns Hopkins University Protein bioconjugation method
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
CN109069636A (zh) 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2018193033A1 (en) 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
EP3934679A1 (en) 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
BR112022020809A2 (pt) 2020-04-15 2023-02-23 Theradaptive Inc Composições e métodos para entrega terapêutica direcionada ao osso
WO2022092915A1 (ko) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
HK1232160A1 (zh) 2018-01-05
TWI750725B (zh) 2021-12-21
CU24455B1 (es) 2019-11-04
CN114133443A (zh) 2022-03-04
AP2016009585A0 (en) 2016-11-30
HUE057845T2 (hu) 2022-06-28
JO3813B1 (ar) 2021-01-31
EP3988170A1 (en) 2022-04-27
TWI792596B (zh) 2023-02-11
TW202039004A (zh) 2020-11-01
KR20170020878A (ko) 2017-02-24
US20180326079A1 (en) 2018-11-15
SG11201609704TA (en) 2017-01-27
CN114099693A (zh) 2022-03-01
ES2905479T3 (es) 2022-04-08
TW201613653A (en) 2016-04-16
PT3157571T (pt) 2022-02-14
US20210000964A1 (en) 2021-01-07
TW202204384A (zh) 2022-02-01
WO2015200078A8 (en) 2016-04-14
PH12016502294B1 (en) 2017-02-13
CN107073130A (zh) 2017-08-18
CR20160596A (es) 2017-05-08
AU2015280351A1 (en) 2016-12-08
SI3157571T1 (sl) 2022-04-29
EA201692466A1 (ru) 2017-04-28
CY1125006T1 (el) 2023-01-05
US11752211B2 (en) 2023-09-12
BR112016028884A2 (pt) 2017-10-31
AU2015280351B2 (en) 2018-07-05
CU20160189A7 (es) 2017-04-05
JP6636959B2 (ja) 2020-01-29
KR102559975B1 (ko) 2023-07-27
UY36186A (es) 2016-01-29
JP6823696B2 (ja) 2021-02-03
CA2953480A1 (en) 2015-12-30
KR20230056796A (ko) 2023-04-27
US10786576B2 (en) 2020-09-29
US10588980B2 (en) 2020-03-17
IL248990B (en) 2019-09-26
US20160030585A1 (en) 2016-02-04
PL3157571T3 (pl) 2022-03-28
CN107073130B (zh) 2021-11-16
JP2017519024A (ja) 2017-07-13
MY193993A (en) 2022-11-07
PH12016502294A1 (en) 2017-02-13
EP3157571B1 (en) 2021-11-24
RS62907B1 (sr) 2022-03-31
LT3157571T (lt) 2022-02-25
AU2015280351C1 (en) 2022-11-24
ECSP17004665A (es) 2018-11-30
DK3157571T3 (da) 2022-02-21
JP2023099133A (ja) 2023-07-11
MA40278A (fr) 2017-04-26
EP3157571A1 (en) 2017-04-26
JP7051959B2 (ja) 2022-04-11
US20240066132A1 (en) 2024-02-29
SG10201912965TA (en) 2020-02-27
HRP20220152T1 (hr) 2022-04-15
CL2016003281A1 (es) 2017-06-09
WO2015200078A1 (en) 2015-12-30
EA039074B1 (ru) 2021-11-30
TWI701048B (zh) 2020-08-11
IL248990A0 (en) 2017-01-31
JP2019206563A (ja) 2019-12-05
TN2016000558A1 (en) 2018-04-04
GT201600263A (es) 2019-07-19
JP2022095757A (ja) 2022-06-28
MX2016017395A (es) 2017-05-01
JP2020203934A (ja) 2020-12-24
MX367520B (es) 2019-08-26

Similar Documents

Publication Publication Date Title
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
CL2010000935A1 (es) Compuestos derivados de niacina unida a un acido graso; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad metabolica tal como hipertrigliceridemia, hipercolesterolemia, diabetes tipo 2 y retinopatia diabetica.
ES2620456T3 (es) Derivados polisacáridos de ácido lipoico, su preparación, uso como productos cosméticos para la piel y dispositivos médicosmédicos
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
ECSP12011631A (es) Composición de insulina de acción prolongada
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
CO6751287A2 (es) Composición antigénetica de micobacteria
CL2011002268A1 (es) Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
AR081339A1 (es) Conjugados peptidicos
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
PE20091007A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
BR112015013071A2 (pt) solução de trombina e seus métodos de uso
CO6400226A2 (es) Micrólido anti-inflamatorio
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
CL2009000478A1 (es) Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson.
AR076910A1 (es) Un agente cosmetico de despigmentacion que comprende un carbohidrato de delta -tocoferilo